MCID: MYC006
MIFTS: 67

Mycosis Fungoides

Categories: Rare diseases, Cancer diseases, Skin diseases, Blood diseases, Immune diseases

Aliases & Classifications for Mycosis Fungoides

MalaCards integrated aliases for Mycosis Fungoides:

Name: Mycosis Fungoides 54 38 12 50 25 52 42 14 69
Alibert-Bazin Syndrome 50 25
Granuloma Fungoides 50 25
Mycosis Fungoides, Unspecified Site, Extranodal and Solid Organ Sites 12
Mycosis Fungoides of Unspecified Site 12
Mycosis Fungoides, Alibert-Bazin Type 56
Mycosis Fungoides Lymphoma 12
Classic Mycosis Fungoides 56
Mycosis Fungoides Nos 12
Mf 12

Characteristics:

Orphanet epidemiological data:

56
classic mycosis fungoides
Inheritance: Multigenic/multifactorial,Not applicable; Prevalence: 1-9/1000000 (Europe); Age of onset: Adult;

OMIM:

54
Inheritance:
familial aggregation without simple mendelian pattern


Classifications:



Summaries for Mycosis Fungoides

OMIM : 54
Mycosis fungoides is a malignant T-cell lymphoma of the skin, first reported (and named) by Alibert (1835). Sezary syndrome is a leukemic variant of mycosis fungoides defined by erythroderma with greater than 80% of the skin showing redness, adenopathy and greater than 1,000 circulating Sezary cells/microliter with a CD4+CD26- or CD4+CD7- phenotype. Sezary cells have a type 2 helper T cell cytokine profile. Sezary syndrome has a median overall survival time of only 2.4 years in patients with Sezary cells at a density of greater than 10,000 cells/microliter or 5.4 years in patients with 1,000-10,000 Sezary cells/microliter. Mycosis fungoides and Sezary syndrome are the most common cutaneous T-cell lymphomas. Sezary syndrome can arise de novo or can appear following years of chronic mycosis fungoides. Both are thought to arise from clonal expansion of CD4+ helper T cells responding to chronic antigen stimulation (summary by Wang et al., 2015). (254400)

MalaCards based summary : Mycosis Fungoides, also known as alibert-bazin syndrome, is related to lymphoma and systemic lupus erythematosus, and has symptoms including hepatomegaly, splenomegaly and alopecia. An important gene associated with Mycosis Fungoides is TNFRSF1B (TNF Receptor Superfamily Member 1B), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Abraxane and Methoxsalen have been mentioned in the context of this disorder. Affiliated tissues include t cells, skin and bone, and related phenotypes are hematopoietic system and immune system

NIH Rare Diseases : 50 mycosis fungoides is a disease in which t-celllymphocytes (a type of white blood cell) become malignant (cancerous) and affect the skin. this condition is one of the most common types of t-cell lymphoma. mycosis fungoides is characterized by a scaly, red rash that develops on the skin, particularly on areas that are not usually exposed to the sun. the rash may last for months or years without causing any symptoms. over time, a thin, reddened, eczema-like rash may develop, followed by thickened, red patches of skin. finally, tumors form which may develop into ulcers and become infected. mycosis fungoides is difficult to cure. treatment is usually palliative, with the intention of relieving symptoms and improving the quality of life. last updated: 1/26/2011

Genetics Home Reference : 25 Mycosis fungoides is the most common form of a type of blood cancer called cutaneous T-cell lymphoma. Cutaneous T-cell lymphomas occur when certain white blood cells, called T cells, become cancerous; these cancers characteristically affect the skin, causing different types of skin lesions. Although the skin is involved, the skin cells themselves are not cancerous. Mycosis fungoides usually occurs in adults over age 50, although affected children have been identified.

Wikipedia : 72 Mycosis fungoides, also known as Alibert-Bazin syndrome or granuloma fungoides, is the most common form... more...

Related Diseases for Mycosis Fungoides

Diseases related to Mycosis Fungoides via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 201)
id Related Disease Score Top Affiliating Genes
1 lymphoma 32.0 CTLA4 IL2 IL5
2 systemic lupus erythematosus 29.6 CTLA4 CXCR3 IFNA1 IL2 IL2RA TNFRSF1B
3 folliculotropic mycosis fungoides 12.4
4 marfan syndrome 11.7
5 cutaneous t cell lymphoma 11.5
6 sezary's disease 11.0
7 toxic diffuse goiter 10.9 CCL17 CXCR3 IL5
8 plagiocephaly and x-linked mental retardation 10.9 CD7 TNFRSF8
9 monofixation syndrome 10.9
10 shprintzen-goldberg syndrome 10.9
11 bolivian hemorrhagic fever 10.9 CCL17 CXCR3 IL2
12 x-linked intellectual disability, van esch type 10.9 CCL22 IL2 IL5
13 nonspecific interstitial pneumonia 10.9 CCL17 CCL22 IL5
14 breast ductal adenoma 10.8 IFNA1 IFNA2
15 cherry allergy 10.8 CCL17 CCL22 IL5
16 cyclosporiasis 10.8 CXCR3 IL2 IL2RA
17 fuchs' heterochromic uveitis 10.8 CCL17 IL2 IL5
18 piussan lenaerts mathieu syndrome 10.8 CD7 TNFRSF8
19 neonatal marfan syndrome 10.8
20 churg-strauss syndrome 10.8 CCL17 CXCR3 IL5
21 benign mammary dysplasia 10.8 IFNA1 IL2 IL5
22 pyridoxine deficiency 10.8 CXCR3 IL5 ITGB2
23 whistling face syndrome, recessive form 10.8 IL2 IL2RA IL5
24 endocardium cancer 10.8 CCL17 CCL22 IL5
25 reese retinal dysplasia 10.8 IFNA2 IL2
26 myelitis 10.8 CXCR3 IL2 IL2RA
27 microspherophakia and/or megalocornea, with ectopia lentis and with or without secondary glaucoma 10.8
28 homocystinuria, b6-responsive and nonresponsive types 10.8
29 renal tubular acidosis 10.8 CXCR3 IL2 IL2RA
30 paramyloidosis 10.7 IL2 IL2RA STAT3
31 central corneal ulcer 10.7 CD7 IFNA2 TNFRSF8
32 cerebral sarcoidosis 10.7 IL2 IL2RA STAT3
33 cerebellar disease 10.7 CCL17 CCL22 CXCR3 IL5
34 laryngeal papillomatosis 10.7 IL2RA STAT3
35 nuchal bleb, familial 10.7 IFNA1 IFNA2
36 myasthenic syndrome, congenital, 7, presynaptic 10.7 CTLA4 CXCL9 CXCR3
37 ganglioneuroblastoma 10.7 CCL17 CCL22 CDKN2B CXCL9
38 acral lentiginous melanoma 10.7 IFNA1 IFNA2 IL2 IL2RA
39 18p deletion syndrome 10.7 CCL17 IFNA1 IL2RA IL5
40 abnormal retinal correspondence 10.6 CTLA4 IL2 IL5
41 scleral disease 10.6 IL2 IL2RA IL5
42 alcoholic hepatitis 10.6 CD7 IL2 IL2RA TNFRSF8
43 gastric ulcer 10.6 CTLA4 IL2 IL5
44 acute necrotizing encephalopathy type 1 10.6 CCL17 CCL22 CXCR3 IL2 IL5
45 graft-versus-host disease, protection against 10.6 IL2 IL2RA
46 thrombocythemia 3 10.6 IFNA1 IFNA2 STAT3
47 diamond-blackfan anemia 3 10.6 CCL17 CCL22 CXCL9 CXCR3
48 epidermolysis bullosa 10.6 CCL17 CCL22 IL5 STAT3
49 localized pagetoid reticulosis 10.6
50 granulomatous slack skin disease 10.6

Graphical network of the top 20 diseases related to Mycosis Fungoides:



Diseases related to Mycosis Fungoides

Symptoms & Phenotypes for Mycosis Fungoides

Symptoms via clinical synopsis from OMIM:

54

Lymphatics:
lymphadenopathy

Skin:
pruritus
erythema
psoriasiform dermatitis
malignant t-cell skin lymphoma
skin scaling
more

Clinical features from OMIM:

254400

Human phenotypes related to Mycosis Fungoides:

56 32 (show all 23)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 hepatomegaly 56 32 occasional (7.5%) Occasional (29-5%) HP:0002240
2 splenomegaly 56 32 occasional (7.5%) Occasional (29-5%) HP:0001744
3 alopecia 56 32 frequent (33%) Frequent (79-30%) HP:0001596
4 hyperkeratosis 56 32 occasional (7.5%) Occasional (29-5%) HP:0000962
5 dry skin 56 32 hallmark (90%) Very frequent (99-80%) HP:0000958
6 lymphadenopathy 56 32 frequent (33%) Frequent (79-30%) HP:0002716
7 edema 56 32 occasional (7.5%) Occasional (29-5%) HP:0000969
8 lymphoma 56 32 Very frequent (99-80%) HP:0002665
9 eczema 56 32 hallmark (90%) Very frequent (99-80%) HP:0000964
10 pruritus 56 32 hallmark (90%) Very frequent (99-80%) HP:0000989
11 hypopigmented skin patches 56 32 frequent (33%) Frequent (79-30%) HP:0001053
12 skin rash 56 32 hallmark (90%) Very frequent (99-80%) HP:0000988
13 erythema 56 32 hallmark (90%) Very frequent (99-80%) HP:0010783
14 poikiloderma 56 32 frequent (33%) Frequent (79-30%) HP:0001029
15 irregular hyperpigmentation 56 32 frequent (33%) Frequent (79-30%) HP:0007400
16 abnormality of the nail 56 32 occasional (7.5%) Occasional (29-5%) HP:0001597
17 skin ulcer 56 32 occasional (7.5%) Occasional (29-5%) HP:0200042
18 abnormality of the eyelid 56 32 occasional (7.5%) Occasional (29-5%) HP:0000492
19 neoplasm of the skin 56 32 hallmark (90%) Very frequent (99-80%) HP:0008069
20 abnormality of bone marrow cell morphology 56 32 occasional (7.5%) Occasional (29-5%) HP:0005561
21 skin plaque 56 32 hallmark (90%) Very frequent (99-80%) HP:0200035
22 abnormality of lymphocytes 56 32 hallmark (90%) Very frequent (99-80%) HP:0004332
23 cutaneous t-cell lymphoma 56 32 frequent (33%) Frequent (79-30%) HP:0012192

MGI Mouse Phenotypes related to Mycosis Fungoides:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.13 CCL17 CD28 CD7 CDKN2B CTLA4 CXCR3
2 immune system MP:0005387 10.03 CCL17 CD28 CD7 CDKN2B CTLA4 CXCR3
3 endocrine/exocrine gland MP:0005379 10.02 CD28 CD7 CDKN2B CTLA4 DPP4 IL2
4 digestive/alimentary MP:0005381 9.91 IL2 IL2RA IL5 STAT3 TNFRSF1B CD28
5 neoplasm MP:0002006 9.5 IL5 STAT3 TNFRSF1B CD28 CDKN2B CXCR3
6 respiratory system MP:0005388 9.17 CTLA4 CXCR3 IL2 IL2RA IL5 STAT3

Drugs & Therapeutics for Mycosis Fungoides

FDA approved drugs:

id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Abraxane 17 46 PACLITAXEL Celgene October 2012

Drugs for Mycosis Fungoides (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 364)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methoxsalen Approved Phase 4,Phase 3,Phase 2,Phase 1 298-81-7 4114
2
Bexarotene Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 153559-49-0 82146
3
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
4
Denileukin diftitox Approved, Investigational Phase 4,Phase 2 173146-27-5
5
Vorinostat Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 149647-78-9 5311
6
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 59-30-3 6037
7
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 58-05-9 143 6006
8 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1
9 Photosensitizing Agents Phase 4,Phase 3,Phase 2,Phase 1
10 Protective Agents Phase 4,Phase 2,Phase 3,Phase 1
11 Anti-Infective Agents Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
12 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1
13 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1
14 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
15 Antiviral Agents Phase 4,Phase 3,Phase 1,Phase 2
16 Folic Acid Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
17 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
18 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
19 Vitamin B Complex Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
20 Pharmaceutical Solutions Phase 4,Phase 2,Phase 1
21 Interferon-alpha Phase 4,Phase 2
22 interferons Phase 4,Phase 2,Phase 1,Early Phase 1
23 Histone Deacetylase Inhibitors Phase 4,Phase 2,Phase 3,Phase 1
24 Clorazepate Dipotassium Phase 4
25 Folate Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
26 Vitamin B9 Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
27
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
28
Amoxicillin Approved, Vet_approved Phase 3 26787-78-0 33613 2171
29
Ciprofloxacin Approved, Investigational Phase 3 85721-33-1 2764
30
Cefepime Approved Phase 3,Phase 1 88040-23-7 5479537
31
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
32
Ofloxacin Approved Phase 3 82419-36-1 4583
33
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 22916-47-8 4189
34
Etoposide Approved Phase 2, Phase 3, Phase 1, Early Phase 1 33419-42-0 36462
35
Fludarabine Approved Phase 2, Phase 3, Phase 1 21679-14-1, 75607-67-9 30751
36
Melphalan Approved Phase 2, Phase 3,Phase 1 148-82-3 4053 460612
37 Thiotepa Approved Phase 2, Phase 3,Phase 1 52-24-4 5453
38
Lenalidomide Approved Phase 3,Phase 1,Phase 2 191732-72-6 216326
39
Doxorubicin Approved, Investigational Phase 2, Phase 3,Phase 1 23214-92-8 31703
40
Panobinostat Approved, Investigational Phase 2, Phase 3, Phase 1 404950-80-7 6918837
41
Darbepoetin alfa Approved, Investigational Phase 3,Phase 2 11096-26-7, 209810-58-2
42
Iron Approved Phase 3,Phase 2,Phase 1 7439-89-6 23925
43
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
44
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
45
Caspofungin Approved Phase 3,Phase 2 179463-17-3, 162808-62-0 468682 2826718
46
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
47
Guaifenesin Approved, Vet_approved Phase 3,Phase 2 93-14-1 3516
48
Morphine Approved, Investigational Phase 3 57-27-2 5288826
49
Ondansetron Approved Phase 3,Phase 2 99614-02-5 4595
50
Lenograstim Approved Phase 3,Phase 2,Phase 1 135968-09-1

Interventional clinical trials:

(show top 50) (show all 379)

id Name Status NCT ID Phase Drugs
1 Photopheresis as an Interventional Therapy for the Treatment of CTCL (Cutaneous T-Cell Lymphoma, Mycosis Fungoides) Stage 1A, 1B, 2A Completed NCT00221039 Phase 4 Methoxsalen+ECP
2 Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients Completed NCT00051012 Phase 4 ONTAK
3 Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients Completed NCT00050999 Phase 4 ONTAK
4 Study Evaluating Two Dose Levels of Targretin Capsules in Patients With Refractory Cutaneous T-cell Lymphoma (CTCL) Completed NCT01007448 Phase 4 bexarotene;bexarotene
5 Comparison of Methotrexate Versus Interferon-alfa 2b in Patients With Primary Cutaneous T-cell Lymphomas Recruiting NCT02323659 Phase 4 Methotrexate;Interferon Alfa-2b
6 PUVA Versus PUVA + IFN Alpha 2a in Mycosis Fungoides Terminated NCT00630903 Phase 4 PUVA (8MOP + UVA) + IFN;PUVA (8-MOP + UVA)
7 Impact of Vorinostat on Pruritus Signaling Pathways - Merck Study Withdrawn NCT01801670 Phase 4
8 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
9 Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
10 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
11 Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma Completed NCT00425555 Phase 2, Phase 3 Panobinostat
12 Study of Oral LBH589 in Adult Patients With Refractory/Resistant Cutaneous T-Cell Lymphoma Completed NCT00490776 Phase 2, Phase 3 LBH589
13 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
14 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3 American ginseng
15 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
16 Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
17 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
18 Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer Completed NCT00070382 Phase 3 darbepoetin alfa;epoetin alfa
19 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
20 Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma Completed NCT00005590 Phase 3 levofloxacin
21 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
22 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
23 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3 ondansetron
24 Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases Completed NCT00438958 Phase 3
25 Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant Completed NCT00305851 Phase 3
26 Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation Completed NCT00045292 Phase 3 acyclovir;acyclovir sodium;valacyclovir
27 Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation Completed NCT00004230 Phase 3 captopril;cyclophosphamide
28 Itraconazole Compared With Fluconazole to Prevent Infections in Patients Undergoing Peripheral Stem Cell or Bone Marrow Transplantation Completed NCT00003883 Phase 3 fluconazole;itraconazole
29 Naloxone Hydrochloride Study for Relief of Pruritus in Patients With Mycosis Fungoides (MF) Form of CTCL Recruiting NCT02811783 Phase 3 Naloxone Hydrochloride Lotion, 0.5%;Placebo Lotion
30 FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides) Recruiting NCT02448381 Phase 3 SGX301 (synthetic hypericin);Placebo
31 PUVA Maintenance Therapy in Mycosis Fungoides Active, not recruiting NCT01686594 Phase 3 8-methoxypsoralen
32 A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma Active, not recruiting NCT01578499 Phase 3 Brentuximab Vedotin;Methotrexate or Bexarotene
33 Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer Active, not recruiting NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
34 Study of Human Monoclonal Antibody to Treat Mycosis Fungoides and Sezary Syndrome Terminated NCT00127881 Phase 3 HuMax-CD4 (zanolimumab)
35 Ultraviolet Light Therapy Using Methoxsalen With or Without Bexarotene in Treating Patients With Mycosis Fungoides Terminated NCT00056056 Phase 3 bexarotene;methoxypsoralen
36 Lenalidomide Maintenance Post-debulking in Advanced CTCL Terminated NCT01098656 Phase 3 lenalidomide
37 Combination Chemotherapy With or Without Etoposide in Treating Older Patients With Non-Hodgkin's Lymphoma Terminated NCT00060385 Phase 2, Phase 3 CHOP regimen;EPOCH regimen;cyclophosphamide;doxorubicin hydrochloride;etoposide;prednisone;vincristine sulfate
38 Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant Terminated NCT00324324 Phase 3 moxifloxacin hydrochloride;Placebo
39 Vorinostat With or Without Bortezomib in Treating Patients With Refractory or Recurrent Stage IIB, Stage III, or Stage IV Cutaneous T-Cell Lymphoma Withdrawn NCT01386398 Phase 3 bortezomib;vorinostat
40 Study of Alemtuzumab to Treat Advanced Mycosis Fungoides/Sezary Syndrome Unknown status NCT00157274 Phase 2 alemtuzumab
41 Combination Chemotherapy in Patients With Advanced or Recurrent Mycosis Fungoides Unknown status NCT00002557 Phase 2 CHOP regimen;doxorubicin hydrochloride;etoposide;leucovorin calcium;methotrexate
42 Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas Unknown status NCT01805037 Phase 1, Phase 2 brentuximab vedotin
43 Lenalidomide as Maintenance Therapy After Combination Chemotherapy With or Without Rituximab and Stem Cell Transplant in Treating Patients With Persistent or Recurrent Non-Hodgkin Lymphoma That is Resistant to Chemotherapy Unknown status NCT01035463 Phase 1, Phase 2 lenalidomide;carmustine;etoposide;cytarabine;melphalan
44 Chemotherapy and Photodynamic Therapy in Treating Patients With Cutaneous T-Cell Lymphoma Unknown status NCT00030589 Phase 2 bexarotene;methoxsalen
45 Combination Chemotherapy Followed by Donor Bone Marrow Transplant or Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Genetic Disorders Unknown status NCT00008307 Phase 2 cyclosporine;fludarabine phosphate;melphalan;methylprednisolone;mycophenolate mofetil
46 Umbilical Cord Blood and Placental Blood Transplantation in Treating Patients With Hematologic Cancer or Aplastic Anemia Unknown status NCT00008164 Phase 2
47 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
48 Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma Unknown status NCT00621036 Phase 2 methotrexate;thiotepa
49 Safety and Efficacy of Nitrogen Mustard in Treatment of Mycosis Fungoides Completed NCT00168064 Phase 2 mechlorethamine-MCH (nitrogen mustard)
50 An Open Label Study to Evaluate the Safety and Efficacy of Mechlorethamine(MCH) 0.04% Formulation in Mycosis Fungoides Completed NCT00535470 Phase 2 0.04% Mechlorethamine gel

Search NIH Clinical Center for Mycosis Fungoides

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Mycosis Fungoides cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: mycosis fungoides

Genetic Tests for Mycosis Fungoides

Anatomical Context for Mycosis Fungoides

MalaCards organs/tissues related to Mycosis Fungoides:

39
T Cells, Skin, Bone, Bone Marrow, B Cells, Liver, Lung

Publications for Mycosis Fungoides

Articles related to Mycosis Fungoides:

(show top 50) (show all 963)
id Title Authors Year
1
Allogeneic hematopoietic stem cell transplantation for refractory mycosis fungoides (MF) and Sezary syndrome (SS). ( 28466385 )
2017
2
Interstitial Mycosis Fungoides: Setting the Record Straight. ( 27984240 )
2017
3
Syringotropic Mycosis Fungoides: A Rare Form of Cutaneous T-cell Lymphoma Enabling a Histopathologic "Sigh of Relief." ( 28692463 )
2017
4
CD30-positive lymphoproliferative Erkrankung bei einem Patienten mit follikulotroper Mycosis fungoides. ( 28485861 )
2017
5
Ultraviolet A1 Phototherapy in the Treatment of Early Mycosis Fungoides. ( 28441652 )
2017
6
Pediatric mycosis fungoides: a study of the human leukocyte antigen system among Israeli Jewish patients. ( 28948342 )
2017
7
Mycosis fungoides with CD30-positive large-cell transformation clinically mimicking scarring alopecia. ( 28834192 )
2017
8
The role of macrophages in the pathogenesis of mycosis fungoides. ( 28436576 )
2017
9
Psoralen-ultraviolet A maintenance in mycosis fungoides: the underlying question. ( 28833012 )
2017
10
Frequency and Risk Factors for Secondary Malignancies in Patients With Mycosis Fungoides. ( 28832009 )
2017
11
Effectiveness of photodynamic therapy in refractory plaque-stage mycosis fungoides associated with Bowen's disease. ( 28198112 )
2017
12
Immunohistopathological Study of c-FLIP Protein in Mycosis Fungoides ( 28952283 )
2017
13
MicroRNA-155 potentiates tumour development in mycosis fungoides. ( 28940265 )
2017
14
Gain of CD26 expression on the malignant T-cells in relapsed erythrodermic leukemic mycosis fungoides. ( 28083948 )
2017
15
Toll-like receptor (TLR)7 expression in mycosis fungoides and psoriasis: a case-control study. ( 28054376 )
2017
16
The effect of phototherapy on progression to tumors in patients with patch and plaque stage of mycosis fungoides. ( 28782389 )
2017
17
Computed Tomography scanning in mycosis fungoides - optimising the balance between benefit and harm. ( 28498608 )
2017
18
Folliculotropic Mycosis Fungoides with Skewed T-cell Receptor CDR3 Motif: Suggestive of Lipid-antigen Selection? ( 28597017 )
2017
19
Concomitant B Hairy Cell Leukemia and Mycosis Fungoides in an Elderly Man. ( 28512405 )
2017
20
Photodynamic therapy: an option in mycosis fungoides. ( 28890210 )
2017
21
Serum vascular endothelial growth factor A levels reflect itch severity in mycosis fungoides and SAczary syndrome. ( 28925057 )
2017
22
Prognostic factors in mycosis fungoides: international advances in the validation of prognostic indices. ( 28504404 )
2017
23
ALK Expression is a Rare Finding in Mycosis Fungoides. ( 28426485 )
2017
24
A possible association between mycosis fungoides and Muir-Torre syndrome: Two disorders with microsatellite instability. ( 28761921 )
2017
25
Mycosis Fungoides in Pediatric Patients: A Diagnostic Challenge. ( 28473054 )
2017
26
No Viral Transcripts Associated with Folliculotropic Mycosis Fungoides Using a High Throughput Sequencing Approach. ( 28448099 )
2017
27
High-frequency ultrasonography in objective evaluation of the efficacy of PUVA and UVA 1 phototherapy in mycosis fungoides. ( 28799043 )
2017
28
Langerhans cell histiocytosis followed by folliculotropic mycosis fungoides. ( 28670259 )
2017
29
Clinical characteristics, risk factors and long-term outcome of 114 patients with folliculotropic mycosis fungoides. ( 28516243 )
2017
30
Underrecognized clinical features of folliculotropic mycosis fungoides: a large clinical series. ( 28240409 )
2017
31
Disseminated CD8-positive, CD30-positive cutaneous lymphoproliferative eruption with overlapping features of mycosis fungoides and primary cutaneous anaplastic large cell lymphoma following remote solitary lesional presentation. ( 28497585 )
2017
32
Oral and Cutaneous Lymphomas other than Mycosis Fungoides and SAczary Syndrome in a Mexican Cohort: Recategorization and Evaluation of International Geographical Disparities. ( 28400635 )
2017
33
Transformation of Mycosis fungoides/Sezary syndrome: clinical characteristics and prognosis. ( 28533196 )
2017
34
Folliculotropic mycosis fungoides associated with atopic dermatitis. ( 28731507 )
2017
35
Feasibility study in teledermatopathology: An examination of the histopathologic features of mycosis fungoides and spongiotic dermatitis. ( 28796294 )
2017
36
CD4-Positive T-Cell Large Granular Lymphocytosis Mimicking Sezary Syndrome in a Patient With Mycosis Fungoides. ( 28441377 )
2017
37
The Results of Low-Dose Total Skin Electron Beam Radiation Therapy (TSEB) in Patients With Mycosis Fungoides From the UK Cutaneous Lymphoma Group. ( 28843374 )
2017
38
Hypopigmented Mycosis Fungoides: Clinical, Histological, and Immunohistochemical Remission Induced by Narrow-band Ultraviolet B. ( 28400643 )
2017
39
Maintenance therapy with psoralen-ultraviolet A for mycosis fungoides: in the absence of evidence sitting on the fence is appropriate. ( 28833022 )
2017
40
Donor-derived mycosis fungoides following reduced intensity haematopoietic stem cell transplantation from a matched unrelated donor. ( 28073814 )
2017
41
Periorbital Involvement in Early Stage Mycosis Fungoides. ( 28421231 )
2017
42
Maintenance phase in PUVA phototherapy of early stage mycosis fungoides. A critically appraised topic. ( 28078669 )
2017
43
Hypopigmented Mycosis Fungoides with Large Cell Transformation in a Child. ( 28804923 )
2017
44
Clinical Outcome and Prognosis of Young Patients with Mycosis Fungoides. ( 28804919 )
2017
45
Lymphoproliferative CD30-positive disorder in a patient with a folliculotropic mycosis fungoides. ( 28387989 )
2017
46
Folliculotropic mycosis fungoides is a heterogenous group. ( 28731259 )
2017
47
Phototherapy of mycosis fungoides. ( 28845954 )
2017
48
Recommendations for treatment in folliculotropic mycosis fungoides: report of the Dutch Cutaneous Lymphoma Group. ( 28132406 )
2017
49
Trichoscopic spectrum of folliculotropic mycosis fungoides. ( 28924975 )
2017
50
Remarkable Advances in the Management of Mycosis Fungoides and the Sezary Syndrome. ( 28423383 )
2017

Variations for Mycosis Fungoides

Cosmic variations for Mycosis Fungoides:

9 (show top 50) (show all 88)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM5574238 ZEB1 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.752A>G p.Y251C 20
2 COSM5574244 ZEB1 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.2668A>C p.T890P 20
3 COSM5574236 ZEB1 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.517C>T p.P173S 20
4 COSM11073 TP53 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.1024C>T p.R342* 20
5 COSM11166 TP53 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.406C>T p.Q136* 20
6 COSM44854 TP53 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.655C>A p.P219T 20
7 COSM44036 TP53 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.296C>T p.S99F 20
8 COSM44312 TP53 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.511G>A p.E171K 20
9 COSM45449 TP53 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.592G>C p.E198Q 20
10 COSM45796 TP53 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.623A>G p.D208G 20
11 COSM10768 TP53 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.535C>T p.H179Y 20
12 COSM110772 TET2 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.4474G>T p.E1492* 20
13 COSM5574229 TET2 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.1918C>T p.Q640* 20
14 COSM42016 TET2 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.4393C>T p.R1465* 20
15 COSM5574231 TET2 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.521C>A p.P174H 20
16 COSM100075 TET2 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.4193T>C p.L1398P 20
17 COSM1716590 STAT5B haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.1924A>C p.N642H 20
18 COSM1717514 STAT3 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.1492A>G p.I498V 20
19 COSM1155743 STAT3 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.1919A>T p.Y640F 20
20 COSM5574219 SETD1A haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.1211G>A p.R404H 20
21 COSM3734685 PLCG1 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.1034C>T p.S345F 20
22 COSM5574251 PLCG1 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.3473G>A p.R1158H 20
23 COSM3734686 PLCG1 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.1559C>T p.S520F 20
24 COSM5049787 PLCG1 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.1025A>G p.D342G 20
25 COSM5049788 PLCG1 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.1024G>A p.D342N 20
26 COSM3405078 PLCG1 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.3487G>A p.E1163K 20
27 COSM580 NRAS haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.181C>A p.Q61K 20
28 COSM4591233 NCOR1 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.534G>C p.K178N 20
29 COSM5574213 NCOR1 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.3360G>C p.E1120D 20
30 COSM5574204 NCOR1 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.6038C>T p.P2013L 20
31 COSM5574211 NCOR1 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.6322C>T p.Q2108* 20
32 COSM126825 NCOR1 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.2125C>T p.Q709* 20
33 COSM5574208 NCOR1 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.76C>A p.Q26K 20
34 COSM5574196 KMT2D haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.11845C>T p.Q3949* 20
35 COSM5574193 KMT2D haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.4475G>C p.S1492T 20
36 COSM30358 KMT2D haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.7495G>A p.D2499N 20
37 COSM5574203 KMT2D haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.5923C>G p.L1975V 20
38 COSM34214 JAK3 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.1715C>T p.A572V 20
39 COSM51374 JAK3 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.1533G>A p.M511I 20
40 COSM5574250 JAK3 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.3067T>C p.Y1023H 20
41 COSM5574248 JAK1 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.2128C>G p.L710V 20
42 COSM2239136 JAK1 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.1961A>T p.Y654F 20
43 COSM3734693 JAK1 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.1975C>T p.R659C 20
44 COSM5574188 DNMT3B haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.2292G>T p.R764S 20
45 COSM1025793 DNMT3B haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.895C>T p.R299* 20
46 COSM5574184 DNMT3A haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.2120G>A p.G707D 20
47 COSM5574186 DNMT3A haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.1752C>A p.Y584* 20
48 COSM220934 CARD11 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.1201G>A p.D401N 20
49 COSM403987 BCOR haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.4274A>G p.N1425S 20
50 COSM5574176 ARID5B haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.1444A>T p.K482* 20

Expression for Mycosis Fungoides

Search GEO for disease gene expression data for Mycosis Fungoides.

Pathways for Mycosis Fungoides

Pathways related to Mycosis Fungoides according to GeneCards Suite gene sharing:

(show all 38)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
14.02 CCL22 CD28 CTLA4 IFNA1 IFNA2 IL2
2
Show member pathways
13.75 CCL17 CCL22 CD28 CDKN2B CXCL9 CXCR3
3
Show member pathways
13.55 CCL17 CCL22 CD28 CXCL9 CXCR3 IFNA1
4
Show member pathways
13.52 CCL17 CCL22 IFNA1 IFNA2 IL2 IL2RA
5
Show member pathways
13.33 CCL22 IFNA1 IFNA2 IL2 IL2RA IL5
6
Show member pathways
13.27 CCL17 CCL22 CD28 CXCL9 CXCR3 IL2
7
Show member pathways
12.91 CCL17 CCL22 CD28 CXCL9 CXCR3 IL2
8
Show member pathways
12.82 CCL17 CCL22 CXCL9 CXCR3 STAT3
9
Show member pathways
12.76 CD28 IFNA1 IFNA2 IL2 IL2RA STAT3
10
Show member pathways
12.76 CD28 CTLA4 CXCL9 IFNA1 IFNA2 IL2
11
Show member pathways
12.57 CD28 IL2 IL2RA IL5 STAT3
12 12.5 CTLA4 IFNA1 IL2 IL2RA ITGB2 STAT3
13
Show member pathways
12.38 CD28 CTLA4 IL2 IL5
14 12.37 CDKN2B IL2 IL2RA ITGB2
15
Show member pathways
12.34 CD28 CTLA4 IL2 IL2RA
16
Show member pathways
12.19 IFNA1 IFNA2 IL2 IL2RA IL5 STAT3
17
Show member pathways
12.14 IFNA1 IFNA2 IL2 IL5
18
Show member pathways
12.01 IL2 IL2RA IL5 STAT3
19
Show member pathways
12 CCL17 CCL22 CXCL9 CXCR3
20 12 CD28 IFNA2 IL2 IL2RA IL5
21 11.94 CCL22 ITGB2 STAT3 TNFRSF1B
22 11.9 IFNA1 IFNA2 IL2 IL2RA STAT3
23
Show member pathways
11.88 CD28 IL2 STAT3
24 11.83 CD7 IL2RA IL5
25 11.79 CD28 CTLA4 ITGB2
26
Show member pathways
11.76 CTLA4 IL2 IL2RA IL5
27 11.71 IFNA2 IL2 ITGAE
28 11.64 CD7 CXCR3 IL2 IL2RA IL5 ITGAE
29 11.59 CD28 CTLA4 TNFRSF8
30 11.5 CCL22 STAT3 TNFRSF1B
31 11.48 CD28 CTLA4 IL2RA IL5 ITGAE ITGB2
32
Show member pathways
11.4 IL2 IL2RA TNFRSF1B
33 11.32 CXCL9 CXCR3 ITGB2
34 11.27 CD28 CTLA4 IL2
35 11.24 CD28 IL2 IL2RA STAT3
36 11.24 CD28 IL2 IL2RA IL5 TNFRSF1B
37 11.2 CCL17 CCL22 CXCL9 IL2 IL5
38 10.77 CCL17 CCL22 CD28 IL2 IL2RA IL5

GO Terms for Mycosis Fungoides

Cellular components related to Mycosis Fungoides according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.81 CCL17 CCL22 CXCL9 DPP4 IFNA1 IFNA2
2 external side of plasma membrane GO:0009897 9.1 CD28 CTLA4 CXCL9 CXCR3 IL2RA ITGAE
3 protein complex involved in cell adhesion GO:0098636 8.96 CD28 CTLA4

Biological processes related to Mycosis Fungoides according to GeneCards Suite gene sharing:

(show all 23)
id Name GO ID Score Top Affiliating Genes
1 apoptotic process GO:0006915 9.99 CXCR3 IFNA2 IL2RA ITGB2 TIA1 TNFRSF1B
2 adaptive immune response GO:0002250 9.85 CD7 CTLA4 IFNA1 IL2
3 negative regulation of inflammatory response GO:0050728 9.78 IL2 IL2RA TNFRSF1B
4 cell surface receptor signaling pathway GO:0007166 9.77 CD28 CXCR3 IFNA2 IL2RA TNFRSF1B
5 T cell costimulation GO:0031295 9.76 CD28 CTLA4 DPP4
6 chemotaxis GO:0006935 9.76 CCL17 CCL22 CXCL9 CXCR3
7 apoptotic signaling pathway GO:0097190 9.74 CD28 TNFRSF1B TNFRSF8
8 neutrophil chemotaxis GO:0030593 9.73 CCL17 CCL22 ITGB2
9 cytokine-mediated signaling pathway GO:0019221 9.73 IFNA1 IFNA2 IL5 STAT3
10 cell-cell signaling GO:0007267 9.73 CCL17 CCL22 CXCL9 IFNA2 IL2 ITGB2
11 positive regulation of T cell proliferation GO:0042102 9.7 CD28 IL2 IL2RA
12 immune response GO:0006955 9.7 CCL17 CCL22 CD28 CD7 CTLA4 CXCL9
13 humoral immune response GO:0006959 9.67 CD28 IFNA1 IFNA2
14 chemokine-mediated signaling pathway GO:0070098 9.62 CCL17 CCL22 CXCL9 CXCR3
15 negative regulation of immune response GO:0050777 9.61 CTLA4 IL2RA
16 positive regulation of immunoglobulin secretion GO:0051024 9.6 IL2 IL5
17 T cell chemotaxis GO:0010818 9.59 CXCL9 CXCR3
18 positive regulation of isotype switching to IgG isotypes GO:0048304 9.58 CD28 IL2
19 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.54 IFNA2 IL2
20 negative regulation of lymphocyte proliferation GO:0050672 9.48 IL2 IL2RA
21 regulation of T cell homeostatic proliferation GO:0046013 9.4 IL2 IL2RA
22 inflammatory response GO:0006954 9.36 CCL17 CCL22 CXCL9 CXCR3 IFNA2 IL2RA
23 regulation of regulatory T cell differentiation GO:0045589 8.85 CD28

Molecular functions related to Mycosis Fungoides according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.17 CCL17 CCL22 CXCL9 IFNA1 IFNA2 IL2
2 type I interferon receptor binding GO:0005132 9.16 IFNA1 IFNA2
3 chemokine activity GO:0008009 9.13 CCL17 CCL22 CXCL9

Sources for Mycosis Fungoides

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....